Early‐stage ROS1 TKIs, such as crizotinib, ceritinib, and entrectinib, can be used in patients with ROS1‐positive NSCLC who have not received TKI treatment (TKI‐naïve).10, 73. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.